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InﬂammationThe P2X7 receptor is an extracellular ATP-gated cation channel critical in inﬂammation and immunity, and
can be up-regulated by IFN-γ and LPS. This study aimed to examine the effect of TGF-β1 on the up-regulation
of P2X7 function and expression in leukemic THP-1 monocytes differentiated with IFN-γ and LPS. Cell-
surface molecules including P2X7 were examined by immunoﬂuorescence staining. Total P2X7 protein and
mRNA was assessed by immunoblotting and RT-PCR respectively. P2X7 function was evaluated by ATP-
induced cation dye uptake measurements. Cell-surface P2X7 was present on THP-1 cells differentiated for
3 days with IFN-γ and LPS but not on undifferentiated THP-1 cells. ATP induced ethidium+ uptake into
differentiated but not undifferentiated THP-1 cells, and the P2X7 antagonist, KN-62, impaired ATP-induced
ethidium+ uptake. Co-incubation of cells with TGF-β1 plus IFN-γ and LPS prevented the up-regulation of
P2X7 expression and ATP-induced ethidium+ uptake in a concentration-dependent fashion with a maximum
effect at 5 ng/ml and with an IC50 of ~0.4 ng/ml. Moreover, ATP-induced YO-PRO-12+ uptake and IL-1β
release were abrogated in cells co-incubated with TGF-β1. TGF-β1 also abrogated the amount of total P2X7
protein and mRNA induced by IFN-γ and LPS. Finally, TGF-β1 prevented the up-regulation of cell-surface
CD86, but not CD14 and MHC class II, by IFN-γ and LPS. These results indicate that TGF-β1 prevents the up-
regulation of P2X7 function and expression by IFN-γ and LPS in THP-1 monocytes. This suggests that TGF-β1
may limit P2X7-mediated processes in inﬂammation and immunity.S, lipopolysaccharide; TGF-β1,
3-acetate; mAb, monoclonal
dy; MFI, mean ﬂuorescence
es, University of Wollongong,
1 2 4221 4135.
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The P2X7 receptor is a trimeric ATP-gated cation channel predom-
inately expressed on lymphoid andmyeloid leukocytes [1,2]. Activation
of this receptor causes the ﬂux of Ca2+, Na+ and K+, as well as the
uptake of large organic cations and anions. The permeability pathways
for these large molecules are unknown, but it appears that more than
onepathwaymay exist and that thesepathways vary between cell types
[3,4]. P2X7 activation can induce a variety of downstream events
including activation of the NALP3 inﬂammasome, and the subsequentmaturation and release of interleukin (IL)-1β and IL-18 [5]. Predomi-
nately due to this property, P2X7 is considered an important sentinel of
immunological danger and infection [6,7], and a potential target of next
generation adjuvants [8]. P2X7 function varies between different
human individuals, which in part, can be explained by numerous
polymorphisms that alter receptor expression and/or function [9,10].
Relative P2X7 expression and function also differs between various
leukocyte subtypes [11,12], and is up-regulated upon differentiation of
monocytes to eithermacrophages [13] or dendritic cells [14]. Moreover,
pro-inﬂammatory molecules such as interferon-γ, (IFN-γ), tumour
necrosis factor-α and lipopolysaccharide (LPS) can up-regulate P2X7
expression and function in monocytes/macrophages [15–17]. The
effects of pro-inﬂammatory molecules on P2X7 are not restricted to
leukocytes, as IFN-γ can also up-regulate P2X7 expression and function
in epithelial cells [18]. However the role of other soluble molecules in
the modulation of P2X7 expression and function remain unknown.
Following on from the pioneering work of Blanchard [19] and Dubyak
[20–22] and their colleagues, the human leukemic monocytic cell line
THP-1 has become a well-established model to study the expression and
functionof P2X7. THP-1 cells expressno to lowamountsof P2X7, however
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with IFN-γ and LPS, or to a lesser extent with 12-myristate 13-acetate
(PMA) [21]. In addition to cation ﬂuxes [21], activation of P2X7 in
differentiated THP-1 cells results in number of downstream signalling
events including: cell lysis [19]; activation of phospholipase D [20],
mitogen-activated protein kinases [23] and caspase-1 [24]; nuclear
translocation of NF-κB [23]; dissociation of nonmuscle myosin from the
P2X7 complex [25] and subsequent inhibition of phagocytosis [26];
release of mature IL-1β [27] and IL-18 [28]; shedding of microvesicles
[29]; and killing of intracellularmycobacteria [30]. THP-1monocytes have
also been widely used to screen a number of potential P2X7 antagonists
leading to the development of some highly speciﬁc and potent P2X7
antagonists [31,32]. Finally, this cell linewasused to establish theblocking
actionof theonly availablehumananti-P2X7monoclonal antibody (mAb)
[16].
Transforming growth factor-β1 (TGF-β1) has pleiotropic effects in a
variety of biological processes including inﬂammation and immunity,
where it is involved in homeostasis and tolerance, as well as the
initiation and resolution of the immune response [33]. As such TGF-β1
has many regulatory roles in restricting the damage caused by the
immune response but without negating the elimination of pathogens
[33]. The action of TGF-β1 varies between cell types and their state of
differentiation, and the combination of cytokines within the extracel-
lular environment [34]. TGF-β1 can down-modulate the expression and
function of several cell-surface receptors including CD1d on dendritic
cells [35], FcεRI on mast cells [36] and Fas on follicular dendritic cells
[37].Whether this important immunomodulatory cytokine affects P2X7
is unknown.Using immunocytochemical andmolecular techniques, and
ﬂuorescent cationdyeuptakemeasurements,wedemonstrate that TGF-
β1 abrogates the up-regulation of P2X7 expression and function by IFN-
γ and LPS in THP-1 cells.
2. Materials and methods
2.1. Reagents
RPMI-1640 medium (containing 10 mM HEPES), LPS (Escherichia coli
055:B5), ATP, ethidium bromide, propidium iodide, trypan blue, nigericin
and DMSOwere from Sigma (St. Louis, MO). FCS (heat-inactivated before
use), gentamycinandGlutaMAXwere from Invitrogen(Grand Island,NY).
Recombinant human IFN-γ and TGF-β1 were from Roche (Mannheim,
Germany), and R&D Systems (Minneapolis, MN), respectively. KN-62 and
7-amino actinomycin D (7AAD) were from Alexis Biochemicals (Lausen,
Switzerland). YO-PRO-12+ was from Molecular Probes (Invitrogen,
Eugene, OR). Protease inhibitor cocktail tablets (complete, Mini, EDTA-
free) and phenyl-methyl-sulfonyl-ﬂuoride were from Roche Diagnostics
(Pensberg, Germany). SuperSignal® West Pico Chemiluminescent Sub-
stratewas fromPierce (Rockford, IL). Other reagent grade chemicalswere
from Sigma or Amresco (Solon, OH).
Murine anti-human P2X7 mAb (clone L4) [16] and isotype control
mAb (clone WMD7) were puriﬁed from hybridoma supernatant and
conjugated to FITC as previously described [11]. FITC-conjugated murine
anti-humanCD14 (clone TUK4) and isotype controlmAbwere fromDako
(Glostrup, Denmark). PE-conjugated murine anti-human CD39 mAb
(clone TU66), FITC-conjugated murine anti-human CD86 (clone 2331)
andMHC class II (HLA-DR; clone L243)mAbwere fromBD (San Jose, CA).
FITC- and PE-conjugated isotype controlmAbwere fromeBioscience (San
Diego, CA) and BD, respectively. Rabbit anti-rat P2X7 (C-termini epitope)
polyclonal antibody (Ab) and blocking peptide were from Alomone Labs
(Jerusalem, Israel). Rabbit anti-actin Ab was from Sigma. Peroxidase-
conjugated goat anti-rabbit IgG Abwas from Rockland (Gilbertsville, PA).
2.2. Cell culture
The human monocytic leukemic cell line, THP-1, was maintained
in RPMI-1640 medium supplemented with 10% FCS, 5 μg/mlgentamycin and 2 mM GlutaMAX (complete media) at 37 °C/5%
CO2. THP-1 cells were differentiated as described [21]. Brieﬂy, cells
were plated at 1×106 cells/ml and cultured for 3 days in 5 ml fresh
completemedia containing 1000 U/ml IFN-γ and 1 μg/ml LPS. TGF-β1
was added as indicated. Untreated THP-1 cells were plated at
3×105 cells/ml and cultured as above.2.3. Cell-surface receptor measurements
THP-1 cells (5×105) were pre-incubated in 100 μl NaCl medium
(145mMNaCl, 5 mMKCl, 5 mMD-glucose, 0.1% BSA, 10 mMHEPES, pH
7.5) containing 10% humanAB+ serum and 0.01%NaN3 for 10 min, then
incubated with ﬂuorochrome-conjugated mAb and 7AAD (to exclude
dead cells) for 20 min, washed and the mean channel ﬂuorescence
intensity (MFI) determined using a FACSCalibur or LSR IIﬂow cytometer
(BD) and Cell Quest software (BD) or FlowJo software (Tree Star,
Ashland, OR) respectively.2.4. Ethidium+ and propidium2+ uptake measurements
Ethidium+ or propidium2+ uptake into THP-1 cells suspended in
KCl medium (150 mM KCl, 5 mM D-glucose, 0.1% BSA, 10 mM HEPES,
pH 7.5), as used extensively by our group for over 17 years to assess
P2X7 pore formation and to avoid the inhibitory effect of Na+ on dye
uptake, was measured by time-resolved ﬂow cytometry as described
[38]. Brieﬂy, THP-1 cells (1×106) were incubated in 1 ml of KCl
medium at 37 °C. Ethidium+ or propidium2+ (both 25 μM) was
added, followed 40 s later by ATP (1 mM). In some experiments, cells
were pre-incubated with KN-62 or DMSO (diluent control) for 5 min.
The linear mean channel of ﬂuorescent cation dye intensity was
measured at 5-s intervals using a FACSCalibur ﬂow cytometer and
WinMDI 2.8 software (http://www.scripps.edu). Ethidium+ or
propidium2+ uptake (P2X7 function) was quantiﬁed as the difference
in arbitrary units of area under the ﬂuorescent cation dye uptake
curves in the presence and absence of ATP during the ﬁrst 5 min of
incubation.2.5. YO-PRO-12+ uptake measurements
YO-PRO-12+ uptake into THP-1 cells suspended in NaCl medium
wasmeasured by a ﬁxed-time ﬂow cytometric assay as described [39].
Brieﬂy, THP-1 cells (1×106) in 1 ml of NaCl medium containing 1 μM
YO-PRO-12+ were incubated in the absence or presence of 1 mM ATP
for 15 min at 37 °C. Incubations were stopped by addition of an equal
volume of ice-cold NaCl medium containing 20 mM MgCl2 and
centrifugation. Cells were washed once with NaCl medium. YO-PRO-
12+ uptake (expressed as MFI) was measured using a LSR II ﬂow
cytometer and FlowJo software.2.6. IL-1β release measurements
ATP- and nigericin-induced IL-1β release from THP-1 cells was
measured using a modiﬁcation of a protocol used previously for
human monocytes [40]. THP-1 cells were suspended at 5×105 viable
(trypan blue exclusion) cells/ml in RPMI-1640 medium containing
0.1% BSA (pH 7.5) and plated into 24-well plates (0.5 ml/well). Cells
were incubated in the absence or presence of 3 mM ATP or 20 μM
nigericin for 15 min at 37 °C/5% CO2. The samples were then
centrifuged at 11,000g for 10 s and the cell-free supernatants stored
at −20 °C for less than 2 weeks before assaying. Amounts of IL-1β
were measured using a human IL-1β ELISA (eBioscience) according to
the manufacturer's instructions.
Fig. 1. P2X7 is present on the cell-surface of differentiated but not undifferentiated THP-1
cells. THP-1 cells, incubated for 3 days in the absence (undifferentiated) or presence
(differentiated) of 1000 U/ml IFN-γ and 1 μg/ml LPS, were labelled with FITC-conjugated
anti-P2X7 (solid line) or isotype control (shaded) mAb and 7AAD, and the relative cell-
surface expression (MFI) determinedbyﬂowcytometry. Representative results fromeight
experiments are shown.
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THP-1 cells were washed three times in ice-cold PBS and then
lysed (1×107 cells/ml) in ice-cold 50 mM BisTris (pH 7.0) containing
750 mM 6-aminohexanoic acid, 1% n-dodecyl β-D-maltoside, 1 mM
phenyl-methyl-sulfonyl-ﬂuoride and a protease inhibitor cocktail
(used according to the manufacturer's instructions) over 60 min,
sheared 10 times through a 21 G needle and centrifuged (16,000g for
10 min at 4 °C). Protein concentrations of cell supernatants were
determined using the CB-XTM Protein Assay (G-Biosciences, St Louis,
MO) according to the manufacturer's instructions. Cell supernatants
(8 μg/lane) were then separated under reducing conditions (5% 2-
mercaptoethanol) using 4–20% gradient iGels (NuSep, Austell, GA)
and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA).
Immunoblotting was performed as described [41] using anti-P2X7 or
anti-actin Ab followed by peroxidase-conjugated anti-rabbit Ig
antibody, and with Ab binding visualized using chemiluminescent
substrate and Amersham Hyperﬁlm ECL (GE Healthcare, Little
Chalfont, Buckinghamshire, UK).2.8. P2X7 expression by RT-PCR
Total RNAwas isolated from cells using the RNeasyMini Kit (Qiagen,
Hilden, Germany) according to the manufacturer's instructions. Previ-
ously described primers to P2X7 (forward primer 5'-GGATGGTGAAC-
CAGCAGCTA-3'; reverse primer 5'-AAGCCACTGTACTGCCCTTC-3') [42]
and β-actin (forward 5'-TGGTGGGCATGGGTCAGAAG-3'; reverse 5'-
GTCCCGGCCAGCCAGGTCCAG-3') [43] were obtained from Sigma-
Genosys (Castle Hill, Australia). PCR ampliﬁcation was performed
using SuperscriptTM III One-Step RT-PCR System Platinum Taq DNA
polymerase (Invitrogen) and corresponding primers for 30 cycles
(95 °C, 15 s; 50 °C, 30 s; 72 °C, 60 s) for P2X7 and 30 cycles (95 °C,
15 s; 61 °C, 30 s; 72 °C, 60 s) for β-actin. PCR products were separated
on a 2% agarose gel and visualized using ethidium bromide staining.2.9. Statistical analysis
Data is presented as the mean±SD. Differences between treat-
ments were compared using either the unpaired Student's t-test for
single comparisons to control samples or ANOVA for multiple
comparisons (using Tukey's post test) using Prism 5 for Mac OS X
Version 5.0a (GraphPad Software, San Diego, CA) with Pb0.05
considered signiﬁcant.Fig. 2. ATP induces ethidium+ uptake into differentiated but not undifferentiated THP-1
cells. THP-1 cells, incubated for 3 days in the absence (undifferentiated; ○, ●) or
presence (differentiated;Δ,▲) of 1000 U/ml IFN-γ and 1 μg/ml LPS, were suspended in
KCl medium at 37 °C. Ethidium+ (25 μM)was added, followed 40 s later by the addition
of 1 mM ATP (arrow). Mean channel of cell-associated ﬂuorescence intensity was
measured by time-resolved ﬂow cytometry for cells incubated in the absence (Δ, ○) or
presence of ATP (▲, ●). Representative results from eight experiments are shown.3. Results
3.1. IFN-γ and LPS up-regulate P2X7 expression and function
Differentiation of THP-1 cells with IFN-γ and LPS over 3 days up-
regulates P2X7 expression and function [21,22]. Therefore, to conﬁrm
these results, THP-1 cells were incubated in the absence or presence of
IFN-γ and LPS as previously described [21], and the amount of cell-
surface P2X7 and ATP-induced ethidium+ uptake (P2X7 function)
measured by ﬂow cytometry. Undifferentiated cells expressed low to
negligible amounts of cell-surface P2X7, whereas cell-surface P2X7was
signiﬁcantly higher on THP-1 cells following differentiation with IFN-γ
and LPS (MFI of 0.9±0.8 and 28.7±13.2 respectively, Pb0.01; Fig. 1).
This difference in the amount of cell-surface P2X7 corresponded with
differences in ATP-induced ethidium+ uptake. ATP induced negligible
amounts of ethidium+ uptake into undifferentiated THP-1 cells, but
induced signiﬁcant ethidium+ uptake into differentiated cells (mean
arbitrary units of ethidium+ uptake of 28±79 and 9456±5087
respectively, Pb0.01; Fig. 2).3.2. The P2X7 antagonist KN-62 impairs ATP-induced ethidium+ uptake
To conﬁrm that the ATP-induced ethidium+ uptake into differen-
tiated THP-1 cells was mediated by P2X7, cells were pre-incubated in
the presence of the P2X7 antagonist KN-62 [44] or DMSO, and the
ATP-induced ethidium+ uptake measured. Pre-incubation with 1 μM
KN-62 inhibited the ATP-induced ethidium+ uptake by 95.1±2.3%
(Fig. 3). Basal ethidium+ uptake in presence of either KN-62 or DMSO
was similar results not shown.
3.3. ATP induces ethidium+ but not propidium2+ uptake
The size exclusion cut-off for P2X7 permeants varies between
different cell types [4]. To partly deﬁne the permeability pathway
followingP2X7 activation indifferentiated THP-1 cells, the ability of ATP
to induce propidium2+ uptake was compared to ethidium+ uptake. As
above, ATP induced ethidium+ uptake into differentiated THP-1 cells
(mean arbitrary units of ethidium+ uptake of 7128±2492; Fig. 4). In
contrast, propidium2+ uptake in the presence of ATP was negligible
(mean arbitrary units of propidium2+ uptake of 31±54; Fig. 4).
3.4. TGF-β1 prevents the up-regulation of P2X7 by IFN-γ and LPS
Next, the effect of TGF-β1 on the up-regulation of P2X7 function was
assessed. THP-1 cellswere incubated for3 dayswithboth IFN-γandLPS in
Fig. 3. The P2X7 antagonist, KN-62, impairs ATP induced-ethidium+ uptake into
differentiated THP-1 cells. THP-1 cells, incubated for 3 days with 1000 U/ml IFN-γ and
1 μg/ml LPS, were suspended in KCl medium at 37 °C. Cells were pre-incubated for 5 min
with eitherDMSO(○,●) or 1 μMKN-62 (▲), ethidium+(25 μM)was then added followed
40 s later by the addition of 1 mM ATP (arrow). Mean channel of cell-associated
ﬂuorescence intensity was measured by time-resolved ﬂow cytometry for cells incubated
in the absence (Δ) or presence of ATP (●, ▲). Representative results from three
experiments are shown.
Fig. 5. TGF-β1 prevents the up-regulation of P2X7 expression and function of IFN-γ and
LPS-treated THP-1 cells. THP-1 cells were incubated for 3 days with 1000 U/ml IFN-γ,
1 μg/ml LPS and 0–10 ng/ml TGF-β1 (as indicated). (A) Cells were labelled with FITC-
conjugated anti-P2X7 or isotype control mAb and 7AAD, and the relative cell-surface
expression (MFI) determined by ﬂow cytometry. (B) Cells were suspended in KCl
medium at 37 °C, ethidium+ (25 μM) was added, followed 40 s later by the addition of
1 mM ATP, and the mean channel of cell-associated ﬂuorescence intensity was
measured by time-resolved ﬂow cytometry. Curves are presented as a percentage of the
maximal (A) cell-surface P2X7 expression or (B) ATP-induced ethidium+ uptake of IFN-
γ and LPS-treated THP-1 cells incubated in the absence of TGF-β1. Results expressed as
the mean±SD (n=5).
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cell-surface P2X7 expression and the ability of ATP to induce
ethidium+ uptake measured. Cell-surface P2X7 expression on differen-
tiatedTHP-1wasabrogated inaconcentration-dependent fashionbyTGF-
β1 with a maximal inhibitory effect observed at 5 ng/ml (69.5±7.3%
inhibition) andwith an IC50 of 0.46±0.25 ng/ml (Fig. 5A). This inhibitory
effect of TGF-β1 on cell-surface P2X7 expression corresponded with
decreased amounts in ATP-induced ethidium+ uptake, with a maximal
inhibitory effect observed at 5 ng/ml (71.7±10.6% inhibition) and with
an IC50 of 0.37±0.25 ng/ml (Fig. 5B).
Next, we examined if delayed addition of TGF-β1 could prevent
the up-regulation of P2X7 expression and function by IFN-γ and LPS.
THP-1 cells were incubated in the presence of IFN-γ and LPS for 3 days
with 10 ng/ml TGF-β1 added on either days 0, 1 or 2. As above, cell-
surface P2X7 expression was signiﬁcantly lower in THP-1 cells
incubated with TGF-β1 for 3 days compared to cells incubated in
the absence of TGF-β1 (Fig. 6A). Cell-surface P2X7 expression on THP-
1 cells incubated with TGF-β1 for the ﬁnal 2 days was lower, albeit notFig. 4. ATP induces ethidium+but not propidium2+uptake into differentiated THP-1 cells.
THP-1 cells, incubated for 3 dayswith 1000 U/ml IFN-γ and 1 μg/ml LPS, were suspended
inKClmediumat 37 °C. Ethidium+ (○,●) or propdium2+ (Δ,▲) (both 25 μM)was added,
followed 40 s later by the addition of 1 mM ATP (arrow). Mean channel of cell-associated
ﬂuorescence intensity was measured by time-resolved ﬂow cytometry for cells incubated
in the absence (○, Δ) or presence of ATP (●, ▲). Representative results from three
experiments are shown.signiﬁcantly, compared to cells incubated in the absence of TGF-β1
(Fig. 6A). Addition of TGF-β1 on the last day of incubation had no
signiﬁcant effect on cell-surface P2X7 expression with values similar
to those of cells incubated in the absence of TGF-β1 (Fig. 6A). A similar
pattern was observed regarding P2X7 function. As above, ATP-
induced ethidium+ uptake was signiﬁcantly lower in THP-1 cells
incubated with TGF-β1 for 3 days compared to cells incubated in the
absence of TGF-β1 (Fig. 6B). ATP induced ethidium+ uptake into THP-
1 cells incubated with TGF-β1 for the ﬁnal 2 days was also
signiﬁcantly lower compared to cells incubated in the absence of
TGF-β1, but to a lesser extent than 3 days incubation with TGF-β1
(Fig. 6B). The addition of TGF-β1 on the last day of incubation had no
signiﬁcant effect on ATP induced ethidium+ uptake with values
similar to those of cells incubated in the absence of TGF-β1 (Fig. 6B).
To demonstrate that that effect of TGF-β1 on P2X7 function was
not limited to ethidium+ uptake or to cells suspended in depolarising
KCl medium, we ﬁrst examined ATP-induced YO-PRO-12+ uptake in
THP-1 cells suspended in NaCl medium as described [39]. ATP induced
signiﬁcant YO-PRO-12+ uptake into THP-1 cells differentiated with
IFN-γ and LPS, but not undifferentiated cells (Fig. 7A). The presence of
TGF-β1 during the incubation of THP-1 cells with IFN-γ and LPS
signiﬁcantly decreased YO-PRO-12+ uptake by 53±1% (Fig. 7A). Next,
we examined ATP-induced IL-1β release from THP-1 cells as described
Fig. 6. Delayed addition of TGF-β1 reduces its efﬁcacy in preventing the up-regulation
of P2X7 expression and function of IFN-γ and LPS-treated THP-1 cells. THP-1 cells
were incubated for 3 days with 1000 U/ml IFN-γ and 1 μg/ml LPS in the absence of
TGF-β1 (0 h), or in the presence of 10 ng/ml TGF-β1 for all 3 days (72 h), the ﬁnal
2 days (48 h) or the ﬁnal day (24 h) of incubation. (A) Cells were labelled with FITC-
conjugated anti-P2X7 or isotype control mAb and 7AAD, and the relative cell-surface
expression (MFI) determined by ﬂow cytometry. (B) Cells were suspended in KCl
medium at 37 °C, ethidium+ (25 μM)was added, followed 40 s later by the addition of
1 mM ATP, and the mean channel of cell-associated ﬂuorescence intensity was
measured by time-resolved ﬂow cytometry. Ethidium+ uptake data are expressed as
arbitrary units of area under uptake curve. Results are expressed as the mean±SD
(n=5); **Pb0.01 compared to 0 h.
Fig. 7. TGF-β1 prevents the up-regulation of ATP-induced YO-PRO-12+ uptake and IL-1β
release of IFN-γ and LPS-treated THP-1 cells. THP-1 cells were incubated for 3 days with
1000 U/ml IFN-γ and 1 μg/ml LPS in the absence or presenceof 10 ng/ml TGF-β1, or in the
absence of IFN-γ and LPS. (A) Cells were suspended in NaCl medium containing 1 μMYO-
PRO-12+, and incubated in the absence or presence of 1 mM ATP at 37 °C for 15 min.
Incubations were stopped by addition of NaCl medium containing 20 mM MgCl2 and
centrifugation, and theYO-PRO-12+uptake (MFI) determined byﬂowcytometry. (B) Cells
were suspended inRPMI-1640mediumcontaining0.1% BSA, and incubated in the absence
or presence of 3 mMATP or 20 μMnigericin for 15 min at 37 °C/5% CO2. The sampleswere
centrifuged and the amount of IL-1β in cell-free supernatants measured by ELISA. Results
are expressed as the mean±SD (n=3); *Pb0.05 and **Pb0.01 to corresponding basal;
††Pb0.01 compared to THP-1 cells differentiated with IFN-γ and LPS, and incubated with
ATP.
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activation, was used as a positive control. ATP induced a small but
signiﬁcant release of IL-1β from THP-1 cells differentiated with IFN-γ
and LPS, but not from undifferentiated cells (Fig. 7B). The presence of
TGF-β1 during the incubation of THP-1 cells with IFN-γ and LPS
decreased IL-1β release by 79±26%, although this failed to reach
statistical signiﬁcance (Fig. 7B). This decrease in ATP-induced IL-1β
release was not due to differences in IL-1β synthesis or release
mechanisms between the two groups as nigericin caused a similar IL-
1β release from differentiated cells incubated in the absence or
presence of TGF-β1 (Fig. 7B).
3.5. TGF-β1 prevents the up-regulation of total P2X7 by IFN-γ and LPS
Human monocytes contain a large pool of intracellular P2X7 [11],
which trafﬁcs to the cell surface during differentiation to macro-
phages [17]. Therefore, to determine if the effect of TGF-β1 in
differentiated THP-1 cells is due to altered P2X7 trafﬁcking or to a
decrease in total P2X7 protein, whole lysates of THP-1 cells were
prepared and the amount of P2X7 examined by immunoblotting.
Actin was included as a loading control. Immunoblotting with an anti-
P2X7 polyclonal Ab failed to detect any bands in untreated THP-1 cellsdespite the presence of actin (Fig. 8A), although a faint band at 75 kDa,
the predicted size of P2X7, was observed in one of the three
experiments performed (results not shown). In contrast, this proce-
dure revealed the presence of a major band at 75 kDa in IFN-γ and
LPS-treated THP-1 cells incubated in the presence or absence of TGF-
β1 (Fig. 8A). Aminor band at 55 kDawas also detected in these cells in
two of the three experiments performed. Of note, the intensity of the
75 and 55 kDa bands were consistently reduced in the IFN-γ and LPS-
treated THP-1 cells incubated in the presence of TGF-β1 compared to
IFN-γ and LPS-treated cells incubated in the absence of TGF-β1,
despite the presence of equal amounts of actin (Fig. 8A). Pre-
Fig. 8. TGF-β1 prevents the up-regulation of total P2X7 protein and mRNA of IFN-γ and
LPS-treatedTHP-1 cells. (A, B)THP-1 cellswere incubated for 3 dayswith1000 U/ml IFN-γ
and 1 μg/ml LPS in the absence (Dx) or presence (TGF) of 10 ng/ml TGF-β1, or in the
absence of IFN-γ and LPS (Nil). (A) Whole cell lysates were separated by electrophoresis,
transferred tonitrocellulosemembraneandprobedwith either (upperpanel) anti-P2X7Ab
or (lower panel) anti-actinAb. (B) (Upper panel) P2X7and (lower panel)β-actinmRNAwas
ampliﬁedbyRT-PCR, separated on a 2% agarose gel and visualisedusing ethidiumbromide
staining. (A, B) Results are representative of three experiments.
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abolished immunoreactivity of both the 75 and 55 kDa bands results
not shown.
3.6. TGF-β1 prevents the up-regulation of P2X7 mRNA by IFN-γ and LPS
Incubation of THP-1 cells with IFN-γ and LPS up-regulates P2X7
mRNA [21]. Therefore, to determine if the effect of TGF-β1 in
differentiated THP-1 cells is due to a decrease in P2X7 mRNA, RNA
was isolated from THP-1 cells and the amount of P2X7 mRNA
examined by RT-PCR. β-actin was included as a house keeping control.
P2X7 mRNA was present in undifferentiated THP-1 cells, and
incubation with IFN-γ and LPS up-regulated P2X7 mRNA expression(Fig. 8B). In contrast, P2X7mRNA expression in IFN-γ and LPS-treated
cells incubated in the presence of TGF-β1 was lower than IFN-γ and
LPS-treated cells incubated in the absence of TGF-β1, despite similar
expression of β-actin mRNA (Fig. 8B).
3.7. The inhibitory effect TGF-β1 on P2X7 is not due to up-regulation of
CD39
The function of purinergic receptors on myeloid leukocytes can be
modulated by presence of cell-surface ecto-nucleotidases such as the
ecto-ATPDase CD39 [45]. Moreover, P2X7 function is lower in
monocyte-derived Langerhans compared to monocyte-derived den-
dritic cells, which corresponds to differences in CD39 but not P2X7
cell-surface expression [14]. Therefore, the possibility remains that
the reduced amount of P2X7 function caused by TGF-β1 in THP-1 cells
is partly due to the up-regulation of CD39. Therefore, the expression of
cell-surface CD39 was assessed. CD39 however was not detected on
either undifferentiated THP-1 cells (MFI of 0.0±0.0; n=3), or on cells
incubated with IFN-γ and LPS in the presence or absence of TGF-β1
(MFI of 0.0±0.0 and 0.0±0.0 respectively; n=3).
3.8. TGF-β1 prevents the up-regulation of CD86 but not CD14 or MHC
class II by IFN-γ and LPS
Differentiation of THP-1 cells with IFN-γ and LPS up-regulates
CD14 [46]. Therefore, it was determined if the TGF-β1 effect on THP-1
cells incubated with IFN-γ and LPS was speciﬁc to P2X7 or could also
affect other cell-surface receptors. THP-1 cells incubated with IFN-γ
and LPS in the presence or absence of TGF-β1, as well as
undifferentiated cells were labelled with a panel of mAb and the
expression of cell-surface markers examined by ﬂow cytometry.
Undifferentiated THP-1 cells expressed negligible to low levels of cell-
surface CD14, CD86 and MHC class II, as well as P2X7 (Fig. 9).
Differentiation of THP-1 cells with IFN-γ and LPS increased the cell-
surface expression of P2X7, CD14, CD86 and MHC class II (Fig. 9). As
above (Figs. 5A and 6A), the presence of TGF-β1 during the incubation
of THP-1 cells with IFN-γ and LPS signiﬁcantly decreased P2X7
expression (Fig. 9). Similarly, TGF-β1 signiﬁcantly decreased CD86
expression on cells incubated with IFN-γ and LPS (Fig. 9). In contrast,
CD14 and MHC class II expression was similar on IFN-γ and LPS-
treated THP-1 cells incubated in the presence or absence of TGF-β1
(Fig. 9).
4. Discussion
P2X7 expression and function can be up-regulated in the human
leukemic monocytic cell line THP-1 upon incubation with IFN-γ and
LPS [21,22]. Using this model of monocyte/macrophage differentia-
tion, we demonstrated that TGF-β1 prevents the up-regulation of
P2X7 by IFN-γ and LPS. The effect of TGF-β1 was maximal at 5 ng/ml,
where it reduced the up-regulation of P2X7 cell-surface expression
and P2X7-induced ethidium+ uptake by ~70%. The effect of TGF-β1
was concentration-dependent with an IC50 of ~0.40 ng/ml. This
inhibitory effect was most prominent when TGF-β1 was present
during the entire 3-day incubation with IFN-γ and LPS, however TGF-
β1 could partially impair P2X7 up-regulation when added 1 day after
the commencement of differentiation with IFN-γ and LPS. The parallel
decrease in cell-surface P2X7 expression and P2X7 function in THP-1
cells parallels observations in leukocytes, where P2X7 function
correlates with cell-surface P2X7 expression [11,17]. Finally, this
effect of TGF-β1 was not limited to ethidium+ uptake, as ATP-induced
YO-PRO-12+ uptake and IL-1β release was also impaired in differen-
tiated THP-1 cells incubated with TGF-β1 compared to differentiated
cells incubated without TGF-β1. Although, it should be noted that the
amount of ATP-induced IL-1β released from THP-1 cells incubated for
3 days with IFN-γ and LPS is lower than the amount of ATP-induced
Fig. 9. TGF-β1 prevents the up-regulation of CD86 but not CD14 orMHC class II of IFN-γ and
LPS-treatedTHP-1cells.UntreatedTHP-1cells, aswell asTHP-1cells incubated for3 dayswith
1000 U/ml IFN-γ and 1 μg/ml LPS in the absence or presence of 10 ng/ml TGF-β1, were
labelled with ﬂuorochrome-conjugated mAb and 7AAD, and the relative cell-surface
expression (MFI) determined by ﬂow cytometry. Results are expressed as the mean±SD
(n=5). *Pb0.05 and **Pb0.01 to untreated THP-1 cells; ††Pb0.01 compared to THP-1 cells
differentiated with IFN-γ and LPS.
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for 6–24 h with LPS [27,29] or for 2 days with IFN-γ and then for 4 h
with LPS [47]. The reason for this difference is unknown, but
prolonged (3 days) incubation of THP-1 cells with LPS and/or possibly
IFN-γ may result in the loss of IL-1β prior to ATP or nigericin
incubation. Alternatively, 3-day incubation of THP-1 cells with IFN-γ
and LPS may not induce large amounts IL-1β synthesis.
The mechanism by which TGF-β1 abrogates the up-regulation of
cell-surface P2X7 by IFN-γ and LPS in THP-1 cells has been partially
elucidated. Immunoblotting of whole cell lysates with anti-P2X7 Ab
demonstrated that TGF-β1 prevents the synthesis of the total amount
of P2X7 protein in differentiated THP-1 cells. Moreover, this reduction
in P2X7 protein paralleled a decrease in P2X7 mRNA expression
suggesting that transcription rather than translation is abrogated by
TGF-β1 in THP-1 cells incubated with IFN-γ and LPS. However, we
cannot exclude the possibility that TGF-β1 may be involved in some
post-transcription event such as increased P2X7mRNA decay, as TGF-
β1 can increase the rate of decay of chemokine mRNA induced by LPS
in murine macrophages [48]. It appears unlikely that the inhibitory
effect of TGF-β1 is due to impaired trafﬁcking of P2X7 as total P2X7
protein amounts were reduced following TGF-β1 treatment, although
impaired trafﬁcking cannot be fully excluded as an additional, albeit
minor, mechanism. The inhibitory effect of TGF-β1 is not due toincreased amounts of a P2X7 variant, which impairs P2X7 expression
and function as observed in some epithelial cell lines [49], as
immunoblotting revealed a decrease in both full-length P2X7
(75 kDa) and a shorter P2X7 variant (55 kDa). The reduced P2X7
function following TGF-β1 incubation was also not due to increased
levels of the ecto-ATPDase CD39. THP-1 cells, regardless of treatment,
failed to express cell-surface CD39, however we cannot exclude the
possibility that other ecto-nucleotidases [50] play an ancillary role in
the reduced P2X7 function in TGF-β1-treated THP-1 cells. Finally, the
inhibitory effect of TGF-β1 is not due to a general block in THP-1 cell
differentiation per se as this cytokine failed to impair the up-
regulation of CD14 and MHC class II.
The THP-1 cell line is a well-established model used to study the
P2X7 and its downstream effects (see Introduction). Moreover, THP-1
cells differentiated with IFN-γ and LPS demonstrate characteristics of
primary macrophages including plastic adherence [21], phagocytosis of
latex beads [26] and killing of intracellularmycobacteria [30]. Our study
conﬁrms the presence of functional P2X7 in THP-1 cells following
differentiation with IFN-γ and LPS. Originally, it was observed that
incubation of THP-1 cells with IFN-γ and LPS up-regulated ATP-induced
cationﬂuxes [21], and then subsequently shown that these cationﬂuxes
were impaired by the P2X7 antagonist KN-62 [22]. Similarly, we found
that KN-62 impaired ATP-induced ethidium+ uptake in differentiated
THP-1 cells conﬁrming that the uptake of this organic cation is also
mediated by P2X7. Our study also conﬁrms the absence of functional
P2X7 in undifferentiated THP-1 cells as observed by others [20,21]. In
contrast another group [23] has demonstrated the presence of
functional P2X7 in undifferentiated THP-1 cells whereby the most
potent P2X7 agonist, 2'- and 3'-0(4-benzoylbenzoyl) ATP, induced
mitogen-activatedprotein kinase activation, NF-κB translocation and IL-
1β release. The reasons for these differences are unknown but may
reﬂect differences in cell lines between laboratories, differences in the
relative sensitivities of the different assays, or differences in the relative
activation thresholds including amounts of cell-surfaceP2X7 expression
required for different P2X7-mediated events. The detection of P2X7
mRNA and low to negligible amounts of cell-surface P2X7, aswell as the
detection of P2X7 protein (in one of three experiments) in undifferen-
tiated THP-1 cells in our study suggests these cells may contain low
amounts of functional P2X7 but whichwere undetectable by our cation
uptake and IL-1β release assays.
The permeability pathways that mediate the passage of large
organic ions following P2X7 activation have not been fully elucidated,
although recent data indicates that the dissociation of non-muscle
myosin from the P2X7 complex may be involved in P2X7 pore
formation [25]. In this study, ATP induced the uptake of ethidium+
(314 Da) and YO-PRO-12+ (375 Da), but not propidium2+ (415 Da)
into differentiated THP-1 cells. This result is similar to those observed
in human lymphocytes [51] and dendritic cells [52], but contrasts
ATP-induced uptake of propidium2+ uptake in osteoblasts [53] and
P2X7-transfected HEK-293 cells [54]. The opening of pannexin-1 has
been implicated in the P2X7-mediated uptake of ethidium+ in
macrophages and P2X7-transfected HEK-293 cells [55], but the
presence of pannexin-1 in THP-1 cells and whether this hemichannel
is permeable to propidium2+ is unknown. Nevertheless our data
suggests that propidium2+ may enter via a different permeability
pathway to that of ethidium+, or that the pore size of the P2X7
permeability pathway may differ between cell types.
In addition to P2X7, IFN-γ and LPS up-regulated the expression of
CD14, CD86 and MHC class II in THP-1 cells. Although various
inﬂammatory stimuli can up-regulate each of these receptors in THP-
1 cells [46,56,57], in relation to incubation with both IFN-γ and LPS
this has only been previously demonstrated for CD14 [46]. Thus, our
study demonstrates that in addition to CD14, incubation with both
IFN-γ and LPS, can also up-regulate CD86 and MHC class II in THP-1
cells. It should be noted however, that in two of the ﬁve experiments
the up-regulation of MHC class II was negligible despite up-regulation
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experiments showed that incubation with IFN-γ and LPS signiﬁcantly
up-regulated MHC class II in THP-1 cells, and that co-incubation with
TGF-β1 did not abrogate expression of this cell-surface molecule
(results not shown). The null effect of TGF-β1 on CD14 andMHC class II
in THP-1 monocytes in the presence of both IFN-γ and LPS contrasts
that observed with macrophages treated with either IFN-γ or LPS
alone, where TGF-β1 inhibits the expression of either CD14 or MHC
class II on IFN-γ- or LPS-treated macrophages respectively [58,59].
The reasons for these differing results are unknown. The action of
TGF-β1 however varies depending on the combination of cytokines
within the extracellular environment [34], thus providing a possible
explanation for the differences observed between the various studies,
apart from differences in cell type.
The inhibitory effect of TGF-β1 on P2X7 in IFN-γ and LPS-treated
THP-1 cells suggests that TGF-β1 may impair the expression and
function of P2X7 on macrophages during inﬂammatory and immune
responses. P2X7 activation can stimulate the NALP3 inﬂammasome to
cause the subsequent release of IL-1β frommacrophages [5]. Thus, TGF-
β1 released during or after infection may serve to reduce ATP-induced
IL-1β release by down-regulating P2X7 in macrophages to limit tissue
injury or to help resolve the immune response. In contrast, the absence
of TGF-β1may allowmaximal P2X7expression and function to promote
ATP-induced IL-1β release during the immune response. Our ﬁndings
also suggest that aberrant TGF-β1 production may contribute to
immune-related disorders in which P2X7 is involved. For example, the
absence of TGF-β1 may help to maintain ATP-induced IL-1β release in
rheumatoid arthritis where a role for P2X7 has been established [60].
Alternatively, increased TGF-β1 release during infection may down-
modulate P2X7 expression in macrophages resulting in impaired ATP-
induced killing of intracellular pathogens. In this regard, loss of P2X7
function, resulting from polymorphic variations in the P2RX7 gene,
results in impaired ATP-induced killing of intracellular Mycobacterium
tuberculosis and Toxoplasma gondi, and increased susceptibility to
tuberculosis and toxoplasmosis respectively [61,62] highlighting the
requirement for optimal P2X7 expression and function to control these
pathogens. Moreover, both these pathogens can induce TGF-β1 release
to suppress macrophage activation to allow their survival and to
promote disease [33], suggesting that down-regulation of P2X7 by this
cytokine during infection may provide an additional mechanism by
which these pathogens can evade destruction.
In conclusion, this study indicates that TGF-β1 can prevent the up-
regulation of P2X7 expression and function by IFN-γ and LPS in THP-1
monocytes, and suggest that TGF-β1 may limit P2X7-mediated
processes during inﬂammatory and immune responses. It will be of
future importance to determine if TGF-β1 can prevent the up-
regulation of P2X7 on macrophages differentiated from primary
monocytes, as well as the effect of TGF-β1 on P2X7 in other cell types.
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